Drug trial halted early for advanced prostate cancer
NCT ID NCT04754425
Summary
This study tested whether a drug called erdafitinib could help control advanced prostate cancer that had stopped responding to standard hormone treatments and spread to the bones. It involved 11 men and aimed to see if the drug could slow cancer growth and reduce bone-related markers in the blood. The trial was also designed to collect blood and bone marrow samples to learn more about how the cancer responds to treatment, but the study was terminated early.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.